Adverum Promotes Angela Thedinga to Chief Technology Officer

Angela Thedinga has been appointed chief technology officer of Adverum Biotechnologies (NASDAQ: [[ticker:ADVM]]). She had joined the Redwood City, CA-based gene therapy developer last August as vice president of program management and strategy. Before Adverum, Thedinga was vice president of program management and chief of staff at AveXis, which is now a subsidiary of Novartis (NYSE: [[ticker:NVS]]). Adverum’s lead program, ADVM-022, is in early-stage testing as a treatment for the “wet” form of age-related macular degeneration.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan